These observations were confirmed by Liebscher and coworkers, showing that ALDH1+ high-grade serous ovarian cancers have a negative prognosis: particularly, the concomitant expression of ALDH1 and EGFR identified a subpopulation of ovarian cancer patients displaying a highly aggressive, poor prognosis disease [270]. This evidence concerns the gene ALDH1A1 and ovarian serous adenocarcinoma.